Our history in 115 years
The company’s origins date back to 1912, when János Köves founded the Phylaxia Vaccine Production Company. His goal was to develop and produce a serum to protect the region's swine herds from swine fever. This marked the beginning of an outstanding research tradition, providing producers with solutions to combat severe diseases.
Famous Hungarian scientists such as József Marek, Aladár Aujeszky, Domokos Derzsy and Adorján Bartha, names that are familiar to veterinarians worldwide, have been closely associated with the development of the company.
For nearly 115 years, Ceva-Phylaxia has operated at the same location, adapting to evolving challenges, setting numerous industry milestones, and driving continuous growth. Our Kőbánya facility is a global benchmark in biological R&D and animal health vaccine production.
The Epidemiological Laboratory of the College of Veterinary Medicine is established under the leadership of Dr. János Köves and Dr. Ferenc Hutyra
Hutyra and Köves establish Phylaxia Serum Production Company
Production of the serum against swine fever begins
Production of human vaccines begins
Dr. Aladár Aujeszky was the first in the world to describe the disease known as pseudorabies
The company is nationalized and given a new name: Phylaxia State Institute for Vaccine Production
The modern central building complex is constructed based on the designs of Ybl Award–winning architects Sára Cs. Juhász and György Rácz
Dr. Rezső Manninger receives the Kossuth Prize for the Phylaxovina sheep pox vaccine
The country’s first premix plant is built
The fermentation tower is built, representing the most advanced manufacturing technology of its time
Production of the vaccine against Aujeszky’s disease begins
Phylaxia merges with the State Vaccine Production Institute, becoming one of the world’s most significant Zinc Bacitracin manufacturers. The company name also changes to: Phylaxia Vaccine and Feed Production Enterprise
Phylaxia builds the largest premix plant in Central Europe
Sanofi privatizes Phylaxia, marking the beginning of a new era and initiating another wave of modernization for the company
The Ceva Group is established through the separation of Sanofi’s animal health division, creating Ceva-Phylaxia Zrt. in Hungary
The Hyogen swine vaccine receives Marketing Authorization
The Coxevac vaccine is used for the first time in the world to protect against a Q fever outbreak
The B5 facility is inaugurated, taking production capacity for poultry Marek's disease vaccines to the next level
The 100 billionth dose of the Transmune vaccine is being produced
We are inaugurating the Linilog warehouse and logistics center in Monor, Europe’s largest cryogenic vaccine storage facility
We have laid the foundation stone for our new manufacturing facility in Monor
Ceva Wildlife Research Fund, empowering science to protect vulnerable animals.